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worldwide, based on a total number of 
17,500 new HAT cases per year (WHO, 
2006). 
 
 The therapeutics currently used in human 
and cattle African trypanosomosis show a 
number of lethal or sublethal side effects 
(Kuzoe, 1993). Moreover the increasing ap-
pearance of chemoresistant parasite strains 
(Mbwambo et al., 1998) necessitates research 
for new active chemical series (Farrell et. al., 
1984, Kinnamon et al., 1989). 
 
Human and livestock are exposed to the risk 
of infection with trypanosomes in an area of 
approximately 10x106km2 in Sub Saharan 
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INTRODUCTION 
Human African Trypanososmosis (HAT), 
or sleeping sickness, is a disease caused by 
infection with the protozoan Trypanosma 
brucei gambiense or Tryapanosoma brucei rho-
desciense, two morphologically identical sub-
species of trypanosome brucei. The two forms 
of the disease are transmitted by tsetse flies 
of the genus Glossina (order Diptera) and 
restricted to sub Saharan Africa. (Trouiler et 
al., 2000). 
 
HAT is a protozoan disease that affects 36 
countries in Sub- Saharan Africa. The most 
recent World Health Organisation preva-
lence estimates are 50,000- 70,000 cases 
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Africa infested with tsetse flies (Leach and 
Robert, 1981). 
 
Currently chemotherapy and chemoprophy-
laxis are the main methods of trypanosomo-
sis control. However the increasing appear-
ance of pathogenic trypanosomes that are 
resistant to the limited number of commer-
cial trypanocides calls for the development 
of new drugs (Rottcher et al., 1985). 
 
HAT is the prototype of a neglected dis-
ease, affecting the poorest people of the 
poorest continent (Trouiler et al., 2002). The 
development of new diagnostic tests and 
drugs has been severely affected by this ne-
glect. (Francois et al., 2005). 
 
Artemisinin, a peroxide-containing ses-
quiterpene lactone isolated from the herb 
Artemisia annua, has been found to possess 
potent antimalaria activity and low toxicity 
both in  animals and humans (China coop-
erative Research group on Quinghaosu and 
its derivatives as antimalarias, 1982). 
 
Artemisinin was originally developed in 
1972 in China (Chinese Institute of material 
medicine) from the plant Artemisia annua 
(sweetworm wood), a sesquiterpene lactone
(empirical formula C15H22O5). Artemisinin 
is the active ingredient in qinghao, a Chi-
nese herb tea that have been used for 150 
years to treat malaria and haemorrhoids. It 
grows in the wild in China and has been 
found to grow in other parts of the world 
too, though the species may vary a bit. Lo-
cally it is prepared as an infusion of the 
dried leaves. (China cooperative Research 
group on Qinghaosu and its derivatives as 
antimalarias, 1982). 
 
Because of their low solubility in either wa-
ter or oil and the short plasma half-life of 
artemisinin, artesunate and artemether have 
been studied, in particular, sodium artesunate 
(Benakis et al., 1997). 
 
All artemisinin derivatives are metabolized to 
an active metabolite: dihydroartemisinin, 
whose half-life is 2 hours compared with the 
45 minutes half life of artesunate (Bich, et al., 
1996). 
 
Artesunate has now been widely used for 
years with great success for the treatment of 
malaria, and its combination with other 
drugs has been strongly promoted by the 
world health organization (WHO) in sub-
Saharan Africa because of high efficacy and 
excellent tolerability. (McIntosh and Olliaro, 
1998). 
 
In general, the endoperoxides have several 
advantages over existing antimalarial drugs, 
firstly there is little or no cross resistance 
with other antimalarial drugs. Secondly, the 
endoperoxides clear the peripheral blood of 
malaria parasites more rapidly than other 
available drugs do. Finally resistance to the 
endoperoxides has not yet developed despite 
widespread clinical use. (White, 1994). 
 
This study is necessary because of increased 
need for alternative therapy in the treatment 
of both human and animal trypanosome. It 
becomes imperative to develop a drug that is 
cheap and easily available and administered 
with short course of administration and to 
which resistance has not occurred. There-
fore, this study is aimed at evaluating the ac-
tivity of different artemisinin group of drugs 
against Trypanosoma brucei both in vivo and in 
vitro with a view to comparing the effective-
ness of artemisinin group of drugs using in 
vivo and in vitro assay methods. 
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MATERIALS AND METHODS 
Source of parasite 
Rats that have been infected with Trypano-
soma brucei (Lafia strain) were obtained from 
the Department of Veterinary Pathology, 
Faculty of Veterinary Medicine, University 
of Ibadan. Blood from the infected rats was 
used to infect mice after five days at a para-
sitaemia level of about 3X103 parasites/ml 
of blood. 
 
Determination of parasitaemia 
Parasitaemia was monitored using blood 
obtained from the tail, presterilized with 
methylated spirit for both rats and mice. 
The number of parasites was determined 
microscopically using the rapid matching 
method of Herbert and Lumsden (1976); 
microscopic counting of parasites in blood 
appropriately diluted with buffered phos-
phate saline (PBS, pH 7.2). 
 
In vivo test 
Forty mice weighing between 25-35g ob-
tained from the Experimental Animal Unit 
of the Department of Veterinary Physiology 
and Pharmacology, University of Ibadan 
were kept in wooden boxes, stabilized for 
two weeks and fed with commercial grow-
ers ration gotten from a local feed mill in 
Abeokuta and water was provided ad libitum. 
The mice were separated into 5 groups (A, 
B, C, D and E) each having 8 mice and 
were stabilized for about 2 weeks before 
they were infected with Trypanosomes. 
Each of the mice was given 1 X 103 para-
sites intraperitoneally in 0.2 ml blood/PBS 
solution. 
 
They were left for 5days to develop parasi-
taemia. 
After 7 days when parasitaemia was estab-
lished, the mice in were treated. The follow-
ing drugs were used; artesunate, 50mg Ar-
tesunat® a commercial artesunate in tablets 
made by Mekophar chemical Pharmaceutical 
Joint stock Company, Artemether, Gvither®
(artemether injection 80mg/1ml ampoule) a 
commercial brand of artemether marketed 
by Greenlife pharmaceuticals limited No 2, 
Banklane Ilupeju, Lagos Nigeria was used. 
Diminazene aceturate Diminal® (445mg di-
minazene diaceurate+ 555 mg phenazone/g, by 
Eagle Chemical Company LTD, Ikeja , Nige-
ria. 
 
 Group A was treated with di-
minazene aceturate at a dose of 
3.5mg/kg given intramuscularly, 
 Group B was given artesunate at a 
dose of 100mg on the first day  and 
50mg for the next five days orally 
using an oral intubator; 
 Group C was treated with artesunate 
per os and diminazene aceturate  in-
tramuscularly at  50mg/kg on the 
first day and 25mg/kg for the next 
four days and 1.75mg/kg respec-
tively, 
 Group D with artemether at a dose 
of 3.2 mg/kg on the first day and 1.6 
mg/kg for the next four days intra-
muscularly and group E were in-
fected  but not treated to serve as 
control. 
 
In vitro test 
Blood sample was taken from infected rat 
with a parasitaemia of about 3X103 trypano-
some/ml (Herbert and Lumsden 1976) into 
an ethylene diamine tetra acetic acid (EDTA) 
containing bottle, 5µl   blood was pipetted 
into each of the 96 well of microtitre plate, 
10µl phosphate buffer saline (PBS) was 
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Trypanocidal activity was tested for in du-
plicates in 96 well micro titer plates (Flow 
laboratories Inc., McLean, Virginia 22101, 
USA). 
 
Fifteen microlitre of blood containing about 
20-25 parasites per field obtained as de-
scribed above was mixed with 5 µl of the 
tested drugs. 
 
Artesunate was thoroughly mixed in dis-
tilled water before usage. Artesunate was 
mixed with diminazene aceturate at half 
their conventional dose for the combination 
therapy before pouring into the microtitre 
plate. Reduction in/stoppage of motility 
under the microscope of trypanosomes in 
wet mount was taken as effective treatment 
for the infection. 
 
To ensure that the effect monitored was 
that of the drug tested alone, a set of con-
trol was included which contained the para-
site suspended in PBS only. 
 
For standard control, test was also per-
formed with the same concentrations of 
Diminal® (445mg diminazene diaceurate+ 555 
mg phenazone/g, Eagle Chemical Company 
LTD, Ikeja, Nigeria). 
 
The microtitre plate was incubated for five 
minutes at 37ºC in an incubator. After incu-
bation few drops of the mixture in each 
well were examined under the microscope 
to check for motility and to determine the 
degree of the motility. Motility was assessed 
for two hours after which there was no 
movement. Whereas the trypanosome sur-
vived for 4-5 hours in the control well in 





Clinical Signs: The infected mice were 
weak, anorexic and emaciated with the skin 
coat appearing rough and starry. There was 
also paleness of the mucous membrane of 
the eyes in groups A-D. 
 
Parasitaemia: The parasites were detected 
in the peripheral blood 5 days post infection 
(dpi). The initial appearance of the trypano-
somes in the blood was followed by a rapid 
increase in the degree of parasitaemia in the 
mice. The parasitaemia rapidly increased dur-
ing the acute phase of the infection and fluc-
tuated during the remaining course of infec-
tion (Fig. 1) 
 
At three days post treatment there was re-
duction in activity of the trypanosomes in 
three groups namely: diminazene aceturate 
group, artemether group, artesunate and di-
minazene group. 
 
Five days after treatment there was complete 
clearance of parasite from three groups: di-
minazene aceturate group, artemether group, 
artesunate and diminazene group. 
 
Seven days post treatment reduction was no-
ticed in the other two groups (artesunate and 
control groups) but the control group started 
dying afterwards. 
 
After 7days, complete clearance was estab-
lished in three groups viz: diminazene acetu-
rate group, artemether group, artesunate and 
diminazene group. 
 
Clinical signs such as dullness and paleness 
of mucous membrane disappeared in the 
infected and treated groups. 
 
The in vitro trypanocidal action of artemissi-
nin group is as presented in Table 2. 
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Figure 1:  Graph showing the degree of parasitaemia in infected mice 
Table 1: In vivo analysis of artemisinin group on trypanosomosis in mice 
TREATMENT PARASITAEMIA       NUMBER OF   DIED   RECOVERED SACRIFICED 
GROUPS            MICE TREATED 
DIMINAZENE 
 
ACETURATE      7.8   8     0  8  8 
ARTESUNATE     7.8   8     1  0  7 
ARTEMETHER    7.8   8     0  8  8 
ARTESUNATE 
& DIMINAZENE 
ACETURATE      7.8   8     2  6  6 
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Table 2: In vitro Analysis of Artesmisinin Group on Trypanosomosis 
 
DRUG & CONCENTRATION  SURVIVAL OF TRYPANOSOMES IN 
MINUTES 
     0 30 60 120 180 240 300 
DIMINAZENE 
ACETURATE         +++ +++ ++ -ve -ve -ve -ve 
ARTESUNATE   +++  +++ +++ ++ -ve -ve -ve 
ARTEMETHER   +++  +++ ++          
ARTESUNATE 
& DIMINAZENE 
ACETURATE    +++    +++ ++ -ve -ve -ve -ve 
CONTROL       




+++: HIGH PARASITAEMIA 
++: MODERATE PARASITAEMIA 
+: LOW PARASITAEMIA 
-VE: NO PARASITAEMIA 
DISCUSSION 
A total of forty mice were used in the in vivo 
analysis from which it was discovered that 
artemether given at the conventional dose 
of 3.2mg stat was found to be effective in 
the treatment of Trypanosoma brucei infection. 
 
In vitro effectiveness of artemether is in line 
with the discovery of Yuliya et al.  (2007). 
The effectiveness observed with artesunate 
and diminazene aceturate combination in 
this study could be due to a synergistic ef-
fect earlier shown by Biobaku et al.  (2008). 
 
Artesunate not been effective in the in vivo 
analysis might be due to oral absorption 
prevention by the dry feed with which the 
mice were fed. 
 
The effectiveness of diminazene aceturate 
still support the fact that it is still an effec-
tive trypanocide and still possess high po-
tency when used correctly. 
 
The group treated with artemether at 3.2mg/
kg stat and 1.6mg/kg/day intramuscularly 
for another four days showed reduction in 
activity of the trypanosomes and complete 
clearance of parasite at three and five days 
after the commencement of treatment. All 
the  mice became active again and were all 
sacrificed. This was the same thing that was 
observed in the diminazene aceturate group 
which is the current available treatment for 
Trypanosomosis. Thus, it can be concluded 
that intramuscular artemether given at above 
stated dose is effective against trypanosomes 
and the potency is comparable to that of di-
minazene aceturate. 
 
The group treated with artesunate at 100mg 
stat and 50mg daily for five days with an oral 
intubator did not show reduction in activity 
or complete clearance at three and five days 
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after the commencement of treatment. Re-
duction in the activity of the trypanosomes 
in this group was noticed at seven day after 
the commencement of treatment in this 
group. This was also noticed in the control 
group. It can be concluded that artesunate 
given at 50mg/kg dose orally is not effec-
tive against Trypanosomoses. The fact that 
one mouse in the artesunate treated group 
died as against four in the control group 
could mean that artesunate has some po-
tency against trypanosomes. The route of 
administration is another thing to consider 
as artesunate was the only agent given orally 
knowing fully well that bioavailability of 
most drugs is higher when given paren-
tarally than orally. The dry feed could have 
also reduced the absorption of artesunate.  
 
Further study using either higher dose orally 
or a parenteral route needed to be done to 
validate this. It has also being said that the 
absorption of artemether is fat dependent 
which might also be responsible for its ef-
fect. 
 
The group treated with artesunate and di-
minazene aceturate in half doses of the indi-
vidual drug also showed reduction in activ-
ity of the trypanosome and complete clear-
ance at three and five days after the com-
mencement of treatment. This could mean 
that diminazene aceturate given in half dose 
is as potent as the current standard dose 
when supplemented with drugs that have 
antitrypanosomal property. It could also 
mean that artesunate have a synergestic ef-
fect with the diminazene aceturate. These 
would need further study. The fact that two 
mice in this group as against none in the 
diminazene aceturate treated group were 
aparasitaemic for 7days could mean that the 
combined drugs in half doses are not as ef-
fective as diminazene aceturate alone given 
in full dose. 
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